KCZ+BZA co-treatment reduced protein expression of Cep70, UPF3A, and RRas2 (Figure 5I,J), shedding new light on the underlying mechanism of combination treatment in HER2-enriched breast cancer and TNBC. This evidence concerns the gene RRAS2 and breast carcinoma.